





COMPLETE LISTING OF ALL PENDING CLAIMS


1. (amended) A compound of **Formula 1, **Formula 2**, **Formula 3** or of **Formula 4****

**Formula 1****Formula 2****Formula 3****Formula 4**

or isomers of the compounds of **Formulas 2** and **3** where the OCH₃, and HF₂CO groups, respectively are linked to the 6 position of the benzimidazole ring, and

wherein **R** represents the groups selected from Formulas (i) through (viii) and (iii);

the dashed line represents the bond connecting the **R** group with the SO₂ group[[,]];:



~~Y is a straight chained or branch chained divalent alkyl group of 1 to 8 carbons, or Y is N;~~

R₁ and **R₂** independently are H, a straight chained or branch-chained di- or trivalent alkyl group of 1 to 12 carbons including 1 or two **R₅** groups, or a straight chained or branch-chained saturated hydrocarbon skeleton having no more than 12 carbons including 1 or two **R₅** groups and optionally further including one to three **X** groups where **X** is independently selected from the group consisting of -O-, -S-, -NR₆-, -NHCO-, -CONH-, -CONHCO-, -COO-, -OCO- and a divalent phenyl group which can optionally be substituted with one or two halogen atoms or with one or two **R₃** groups; or the **R₅** group is directly attached without an intervening **R₁** or **R₂** group to the aromatic or heteroaromatic ring or to the **Y** group of formulas **(i)** through **(viii)**;

R₃ and **R₄** independently are H, alkyl of 1 to 3 carbons, fluoroalkyl of 1 to 3 carbons, O-alkyl of 1 to 3 carbons, O-fluoroalkyl of 1 to 3 carbons, S-alkyl of 1 to 3 carbons, S-fluoroalkyl of 1 to 3 carbons;

R₅ is independently H, COOH or a tetrazole moiety;

R₆ is H or alkyl of 1 to 3 carbons;

with the provisos that

at least one the **R₁** and **R₂** groups is not H, and

at least one **R₅** is not H and no more than two **R₅** groups are COOH or tetrazole whereby the compound includes at least one but no more than two COOH or tetrazole groups;


~~when **Y** is N then neither of the **R₁** and **R₂** groups is H,~~

or a pharmaceutically acceptable salt of said compound.

2. (Original) A compound in accordance with Claim 1 which has the structure in accordance with **Formula 1**.

3. (Original) A compound in accordance with Claim 1 which has the structure in accordance with **Formula 2**.

4. (Original) A compound in accordance with Claim 1 which has the structure in accordance with **Formula 3**.
5. (Original) A compound in accordance with Claim 1 which has the structure in accordance with **Formula 4**.
6. (Original) A compound in accordance with Claim 1 where R_5 is independently selected from H and COOH, or a pharmaceutically acceptable salt of said compound.
7. (Original) A compound in accordance with Claim 1 where the formula includes at least one **X** group.
8. (Original) A compound in accordance with Claim 1 where at least one **X** is O.
9. (Original) A compound in accordance with Claim 1 where at least one **X** is CONH.
9. (Original) A compound in accordance with Claim 1 having two R_5 groups which represent COOH, or a pharmaceutically acceptable salt of said compound.
10. (Original) A compound in accordance with Claim 1 where **R** represents **formula (i)**.
11. (Original) A compound of **Formula 1a**, **Formula 2a**, **Formula 3a** or of **Formula 4a**



or isomers of the compounds of **Formulas 2a** and **3a** where the OCH₃, and HF₂CO groups, respectively are linked to the 6 position of the benzimidazole ring,

R₁ and **R**₂ independently are H, a straight chained or branch-chained di- or trivalent alkyl group of 1 to 12 carbons including 1 or two **R**₅ groups, or a

straight chained or branch-chained saturated hydrocarbon skeleton having no more than 12 carbons including 1 or two \mathbf{R}_5 groups and optionally further including one to three \mathbf{X} groups where \mathbf{X} is independently selected from the group consisting of -O-, -S-, -NR₆-, -NHCO-, -CONH-, -CONHCO-, -COO-, -OCO- and a divalent phenyl group which can optionally be substituted with one or two halogen atoms or with one or two \mathbf{R}_3 groups; or the \mathbf{R}_5 group is directly attached without an intervening \mathbf{R}_1 or \mathbf{R}_2 group to the aromatic or heteroaromatic ring or to the \mathbf{Y} group of formulas **(i)** through **(viii)**;

\mathbf{R}_3 and \mathbf{R}_4 independently are H, alkyl of 1 to 3 carbons, fluoroalkyl of 1 to 3 carbons, O-alkyl of 1 to 3 carbons, O-fluoroalkyl of 1 to 3 carbons, S-alkyl of 1 to 3 carbons, S-fluoroalkyl of 1 to 3 carbons;

\mathbf{R}_5 is independently H or COOH;

\mathbf{R}_6 is H or alkyl of 1 to 3 carbons;

with the provisos that

at least one the \mathbf{R}_1 and \mathbf{R}_2 groups is not H, and

at least one \mathbf{R}_5 is not H and no more than two \mathbf{R}_5 groups are COOH whereby the compound includes at least one but no more than two COOH groups; or a pharmaceutically acceptable salt of said compound.

12. (Original) A compound in accordance with Claim 11 that has
Formula 1a.

13. (Original) A compound in accordance with Claim 11 that has
Formula 2a.

14. (Original) A compound in accordance with Claim 13 where the CH₃O group is in the 5 position of the benzimidazole moiety.

15. (Original) A compound in accordance with Claim 11 that has
Formula 3a.

16. (Amended) A compound in accordance with Claim [[13]] 15 where the HF₂CO group is in the 5 position of the benzimidazole moiety.





17. (Original) A compound in accordance with Claim 11 that has **Formula 4a**.

18. (Original) A compound in accordance with Claim 11 that includes only one COOH group, or its pharmaceutically acceptable salt.


19. (Original) A compound in accordance with Claim 11 that includes only two COOH groups, or its pharmaceutically acceptable salt.


20. (Original) A compound in accordance with Claim 11 where R₂, R₃ and R₄ are hydrogen and R₁ is OCH₂COOH attached in the 4 position on the phenyl ring relative to the sulfonyl group, or its pharmaceutically acceptable salt.

21. (Original) A compound of **Formula 1**, **Formula 2**, **Formula 3** or of **Formula 4**

**Formula 1****Formula 2****Formula 3****Formula 4**

or isomers of the compounds of **Formulas 2** and **3** where the OCH₃, and HF₂CO groups, respectively are linked to the 6 position of the benzimidazole ring, and wherein **R** represents the groups selected from **Formulas (a)** through **(s)**, the dashed line represents the bond connecting the **R** group with the SO₂ group,





or a pharmaceutically acceptable salt of said compound.

22. (Original) A compound in accordance with Claim 21 of **Formula 1**.

23. (Original) A compound in accordance with Claim 21 of **Formula 2**.


24. (Original) A compound in accordance with Claim 23 where the CH₃O group is in the 5 position of the benzimidazole moiety.

25. (Original) A compound in accordance with Claim 21 of **Formula 3**.

26. (Original) A compound in accordance with Claim 25 where the HF₂O group is in the 5 position of the benzimidazole moiety.

27. (Original) A compound in accordance with Claim 21 of **Formula 4.**

28. (Original) A compound in accordance with Claim 21 that has the formula



or a pharmaceutically acceptable salt of said compound.

29. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound in accordance with Claim 1.

30. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound in accordance with Claim 11.

31. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound in accordance with Claim 21.

32. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound in accordance with

Claim 28.

33. CANCELED